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Abstract
Metformin is the most commonly used pharmacological therapy for type 2 diabetes. We carried
out a GWA study on glycaemic response to metformin in 1024 Scottish patients with type 2
diabetes. Replication was in two cohorts consisting of 1783 Scottish patients and 1113 patients
from the UK Prospective Diabetes Study. In a meta-analysis (n=3920) we observed an association
(P=2.9 *10−9) for a SNP rs11212617 at a locus containing the ataxia telangiectasia mutated
(ATM) gene with an odds ratio of 1.35 (95% CI 1.22 to 1.49) for treatment success. In a rat
hepatoma cell line, inhibition of ATM with KU-55933 attenuated the phosphorylation and
activation of AMPK in response to metformin. We conclude that ATM, a gene known to be
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involved in DNA repair and cell cycle control, plays a role in the effect of metformin upstream of
AMPK, and variation in this gene alters glycaemic response to metformin.
In treating Type 2 diabetes metformin is recommended as first line therapy in most national
and international guidelines1,2. Despite the clinical use of metformin for over 50 years, its
mechanism of action has not been fully elucidated. Whilst it is established that metformin
activates AMP-activated protein kinase (AMPK)3 by inhibition of the mitochondrial
respiratory chain4, causing an increase in cellular AMP5, it remains uncertain whether
AMPK is its sole therapeutic target.
There is considerable variability in glycaemic response to metformin. No clinical phenotype
usefully predicts response6 yet there has been little pharmacogenetic investigation of
metformin with no consistently replicated genetic variant established. We hypothesised that
a GWA approach could be applied to the glycaemic response to metformin to gain insight
into the mechanism of metformin’s action in humans, and to identify variants that may be
useful clinically to predict efficacy or adverse outcome.
As part of the Wellcome Trust Case Control Consortium 2 study (WTCCC2), a GWA study
of 15 complex traits and disorders, we carried out the first GWA study on metformin
response in patients with type 2 diabetes, using a large Scottish observational genetic cohort
(GoDARTS) of European ancestry. As our principal outcome phenotype, we used the ability
to reduce HbA1c (the most widely used measure of medium term glycaemic control) in the
first 18 months of therapy to below 7%, this being a key measure of success in many
treatment algorithms. Covariates shown to alter metformin response, such as baseline
HbA1c and creatinine clearance were included in a logistic regression model (supplementary
methods). Full details of the cohorts and models used are available in the online methods
and baseline characteristics of the cohorts are shown in supplementary figure 1 and
supplementary table 1. Samples were genotyped using the Affymetrix 6.0 microarray. After
strict quality control we analysed 705,125 SNPs in 1024 metformin treated patients
(supplementary methods). The quantile-quantile plot is shown in supplementary figure 2; the
genomic inflation factor was 1.003. The Manhattan plot is shown in supplementary figure 3.
We found that 14 SNPs with a p-value <1*10−6 mapped to a 340 kb strong LD block on
chromosome 11q22 (figure 1). No stronger association was observed around this locus after
imputing the data to the 2.2 million HapMap II CEU panel. SNPs at other loci, that are
potentially associated with metformin response, did not achieve a p-value lower than 1*10−6
and have not been followed up in the current study (supplementary table 2). The minor allele
(C) of the most strongly associated SNP, rs11212617, had a frequency of 44% and was
associated with treatment success (achieving an HbA1c below 7%) with an allelic odds ratio
of 1.64 (95% Confidence interval 1.37 to 1.99, p=1.9*10−7) (table 1). The full model is
shown in supplementary table 3a.
Our primary analysis used a binary treatment target as its endpoint. To check the robustness
of this, we also analysed the treatment HbA1c as a quantitative trait in a linear regression. In
parallel with the primary analysis we found the C allele of rs11212617 was associated with
lower treatment HbA1c (per allele Beta −0.18% [95% confidence intervals −0.26 to −0.1],
p=1.8*10−5) (table 1).
Two replication cohorts were used. SNP rs11212617 was genotyped in an independent
GoDARTS cohort of 1783 metformin-treated patients with type 2 diabetes (replication 1).
The minor allele (C) of rs11212617 was associated with treatment success (allelic OR 1.21
95%CI 1.05 to 1.38; p=0.007) (table 1). The second replication cohort was 1113 UK patients
prospectively treated with metformin in the UKPDS (UK Prospective Diabetes) cohort
(replication 2). The UKPDS was a prospective randomised clinical trial of intensive vs
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conventional treatment in type 2 diabetes. In the UKPDS, where, for technical reasons, we
typed the proxy SNP rs609261 (r2=0.997 with rs11212617 in 5197 WTCCC2 controls) the
minor allele was associated with treatment success (allelic OR 1.37 95%CI 1.1 to 1.72;
P=0.006) (table 1). The combined p-value achieved significance of p=2.9*10−9 for 3920
metformin-treated patients (table 1). The full models for each cohort are shown in
supplementary table 3a-c. In the combined linear regression, each copy of the rs11212617
minor allele C is associated with 0.11% (p=6.6*10−7) lower absolute treatment HbA1c
(table 1).
Metformin can be used as monotherapy alone, or added in to other therapies. However,
current prescribing practice is for metformin to be used first line; we therefore analysed the
monotherapy subgroup separately. Most of the association signal at rs11212617 with
metformin response for the full group arises from the monotherapy subgroup
(supplementary table 4). In a meta-analysis of this monotherapy group (n=2264) the
combined odds-ratio for treatment success was 1.42 (95% CI 1.26 to 1.62), p=4*10−8. To
assess the clinical impact of rs11212617, we studied the UKPDS cohort that was randomly
assigned to metformin monotherapy (n=284) and followed up prospectively, and therefore
not prone to treatment selection bias. In this subgroup, the 19% of patients with two copies
of the C allele at rs11212617 have a 3.3-fold greater likelihood of achieving an HbA1c
<=7%. This equates to a model adjusted difference in treatment HbA1c of 0.61% between
those who are CC vs AA at this SNP. Adding genotype to the full linear regression model in
this UKPDS group randomised to metformin increased the variance in the treatment HbA1c
explained by the model from 27.5% to 30% (p=0.007).
To ensure that the genotypic effect on metformin response was not related to an effect on
HbA1c per se, and to assess the association with fasting insulin and HOMA derived insulin
resistance, we analysed summary statistics for rs11212617 from the Meta-Analyses of
Glucose and Insulin-related traits Consortium (MAGIC)7. We found no association of
rs11212617 with HbA1c (p=0.82), HOMA-IR (p=0.99) and fasting insulin (p=0.73) in at
least 35,914 non-diabetic individuals (supplementary methods). We found no association
between baseline HbA1c and rs11212617 in the GoDARTs discovery or replication dataset.
In addition there was no association of rs11212617 with lipid parameters, blood pressure,
height, weight, BMI, adiponectin and leptin in up to 6148 Scottish controls (supplementary
table 5); nor with type 2 diabetes risk in a case-control study of 5788 Scottish GoDARTS
patients with type 2 diabetes and 6357 non-diabetic Scottish GoDARTS controls (p=0.64).
The SNP rs11212617 falls within a large block of linkage disequilibrium that includes the
genes CUL5, ACAT1, NPAT, ATM, C11orf65, KDELC2, EXPH5. Of these, ATM was
considered a possible candidate gene. Firstly, homozygous loss of function mutations in
ATM cause Ataxia Telangiectasia (A-T; OMIM #208900) which is a neurodegenerative
disorder characterized by loss of muscle coordination and progressive ataxia,
radiosensitivity, immunodeficiency and a predisposition to cancer8; additionally, patients
with A-T have been reported to have marked insulin resistance and increased risk of
diabetes9,10. Secondly, previous laboratory reports suggest that activation or inhibition of
ATM alters AMPK activation11-13. None of the other genes at the locus have been reported
to be associated with diabetes or insulin action.
ATM encodes a 370 kDa protein that is a Ser/Thr protein kinase of the atypical
phosphoinositide 3-kinase-related protein kinase (PIKK) family. ATM is activated by
double-stranded DNA breaks, and acts to induce cell-cycle arrest and facilitate DNA
repair14. To investigate if ATM was the causal gene affecting the glycaemic response to
metformin we studied the effects of a selective ATM inhibitor, KU-55933, on the activation
of AMPK by metformin in rat hepatoma (H4IIE) cells. Figure 2 shows that KU-55933
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markedly reduced AMPK activation by metformin. Similarly, figure 3 shows that
phosphorylation of AMPK and its downstream target, ACC, by metformin was inhibited by
KU-55933. These results are supported by previous reports of ATM involvement in the
activation of AMPK by stimuli other than metformin11-13. We conclude that ATM acts
upstream of AMPK, and is required for a full response to metformin. ATM is also reported
to be involved in insulin signalling and pancreatic β-cell dysfunction, both of which may
influence metformin action: apoE −/− mice heterozygous for loss of atm function were
insulin-resistant compared to apoE−/− mice with normal atm15; however, mice lacking atm
develop diabetes due to β cell dysfunction16.
Potential functionality of all the 98 SNPs with strong linkage disequilibrium (r2 >0.8
according to the HapMap CEU panel) to rs11212617 was assessed (supplementary table 6).
SNP rs228589, which is in intron 1 of the NPAT gene, is in a predicted promoter of ATM17.
Two SNPs, rs227092 and rs4585, are located in the ATM 3′UTR region. Variant rs4585 lies
24bp downstream of a polyadenylation site, and is predicted to alter efficiency of
polyadenylation (supplementary table 6). The 3′UTR region of ATM is among the longest
known mammalian 3′UTRs and has been suggested to influence ATM mRNA translation
allowing rapid response to stimuli at the post-transcriptional level18,19.
Type 2 diabetes is associated with increased cancer risk, and an overlap between genes
predisposing to prostate cancer and type 2 diabetes has been described20. Metformin has
been shown in epidemiological studies to be associated with decreased cancer risk21, and to
decrease tumour burden in pten deficient mice22. Activation of AMPK by metformin
requires the known tumour suppressor LKB1. In this study the implication of ATM, a gene
known to be involved in DNA repair and cancer, in the glycaemic response to metformin
establishes a further link between cancer pathways, type 2 diabetes and metformin activation
of AMPK.
In this study, we have established the utility of a genome wide approach to study the
pharmacogenomics of metformin response, and the utility of large genetics resources linked
to routinely collected clinical data for pharmacogenetic studies. We have identified the first
robustly replicated variant to be associated with metformin response. Whilst this observation
may not be of immediate clinical utility, explaining only 2.5% of variance in metformin
response, this study is an example of how genome-wide association studies can be applied to
pharmacogenomic models to identify novel pathways and mechanisms, and has established
an unexpected link between glucose homeostasis and the DNA damage response.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
On Line Methods
Samples
The discovery cohort and first replication cohort were both ascertained from the Diabetes
Audit and Research Tayside Study (DARTS)23. Validated prescribing data, biochemistry
data as well as clinical phenotypes back to 1992 can be retrieved from central databases for
all the DARTS patients. Prospective longitudinal data were also collected on these patients.
Since October 1997, all patients with diabetes have been invited to give written informed
consent to DNA as part of the Wellcome Trust United Kingdom Type 2 Diabetes case
control collection. As of June 2009, 8000 cases and 7000 controls of European ancestry
have participated in this Genetics of DARTS (GoDARTS) study.
As part of the WTCCC2, 4134 GoDARTS cases were selected primarily for a genome wide
association study of statin response, but also for a study of response to oral hypoglycaemic
agents (OHA). Following the WTCCC2 genotyping quality control (see below), 1024
patients were identified who were initiated on metformin and had a definable metformin
response (discovery cohort). Of the GoDARTS cases not in the WTCCC2 discovery cohort
metformin response could be defined in 1783 patients and this was used for the first round
replication.
The second replication cohort was patients with type 2 diabetes either randomised to
metformin, or treated with metformin as per protocol, in the UK Prospective Diabetes Study
(UKPDS)24. A total number of 1113 white European patients, who were exposed to
metformin and passed the genotyping quality control, were identified in the UKPDS cohort.
These were either primarily randomized to metformin (n=284), were randomized second
line as add-in to sulphonylureas (n=231), or had metformin added to sulphonylurea per
protocol for symptomatic hyperglycaemia or when fasting glucose was greater than
15mmol/L (n=598).
Phenotypes
Because over 92% of the OHA prescriptions issued in GoDARTS cohort are either
metformin (51.4%) or sulphonylurea (41.2%), we focused on two treatment schemes of
metformin monotherapy (metformin added in following failure of dietary control) or dual
therapy (metformin added to stable sulphonylurea treatment).
Following initiation of oral hypoglycaemic agents in type 2 diabetes, there is an initial
reduction in HbA1c, followed by a gradual deterioration. This can be seen in both the
UKPDS study and other diabetes trials such as ADOPT25. The gradual deterioration in
HbA1c will reflect both drug efficacy (or inefficacy) to control HbA1c, and the underlying
diabetes progression. To target the drug response alone we focused on the first 18 months of
metformin therapy to minimize the response window but ensure minimal exclusion due to
lack of HbA1c data.
In this observational study, the patient’s physician will be treating to achieve an HbA1c
target, which over the majority of the study period would have been 7%. We therefore
defined our primary drug response phenotype as a dichotomous trait of treatment success
which was the ability to achieve an HbA1c below 7% in the first 18 months of treatment,
with censoring if diabetes therapy was changed prior to this. Our secondary analysis took the
quantitive phenotype as treatment HbA1c which was the lowest HbA1c observed between 1
and 18 months after metformin treatment or prior to a change in therapy (cessation of
metformin or addition of further oral hypoglycaemic therapy).
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The two phenotypes were modelled with multiple linear or logistic regression using the
same set of covariates which includes baseline HbA1C, adherence, daily dose, creatinine
clearance, baseline gap and treatment group. More details of the models and covariates were
provided in supplementary methods.
In the UKPDS the HbA1c was measured yearly, and the HbA1c measure closest to 1 year
after commencing metformin was taken as the treatment HbA1c. In the cases randomized to
metformin this would have been approximately one year after starting metformin; in those
starting metformin as per protocol due to hyperglycaemia the time between starting
metformin and the treatment HbA1c was variable so an additional covariate (treatment gap)
was included in the model. Treatment success was a treatment HbA1c <=7%. Other
covariates included were as for the GoDARTS models, except adherence and dose were not
included due to missing data.
GWAS genotyping and Quality Control (QC)—Samples were genotyped at
Affymetrix’s service laboratory on the Genome-Wide Human SNP Array 6.0. Genotype data
quality control was via the standard protocol that was established for the WTCCC2 studies26
(supplementary methods). Specifically, concordance check was performed on 116 SNPs by
1779 individuals overlapped between this GWA data and the WTCCC1 T2D case control
study27. Based on the concordance rate of 99.73%, individuals with more than 10%
discordance were removed from the current study. After such stringent QC, the clean data
set included 705125 autosomal SNPs on 3736 samples, of whom 1024 have definable
metformin response.
Replication Genotyping—In the first round replication, following assay optimization of
the top two SNPs from the GWA (rs11212617 and rs624366, r2=0.997 in 3736 GoDARTS
samples), rs11212617 had better genotyping performance and was genotyped by the
standard Taqman-based allelic discrimination method (Applied Biosystems) in the whole
GoDARTS cohort, which included 7000 non-diabetic controls. The overall call rate was
98.3% with a concordance rate of 99.9% to the GWA genotypes. There was no deviation
from Hardy Weinberg Equilibrium (p=0.44). Minor allele C had a frequency of 43.9% in the
1783 GoDARTS replication sample.
Taqman was also used for genotyping the UKPDS replication sample. Following
optimization of 4 highly correlated SNPs (rs11212617 and rs624366 as well as two proxies
rs609261 and rs2345801) in a subset of UKPDS samples, SNP rs609261 was selected and
genotyped based on better genotyping performance than the other SNPs. rs609261 is almost
a perfect proxy for rs11212617 (r2=0.997 in 5197 WTCCC2 controls) and as such, results
are presented as for rs11212617 in the UKPDS cohort. Genotyping of all available UKPDS
DNAs (n=3400) was carried out in duplicate using standard conditions. Discrepancy
between the duplicate genotyping runs was 0.4%, and only samples for which the duplicate
genotypes were concordant were analysed. The final UKPDS replication cohort included
1113 Caucasian patients and the minor allele frequency was 42.1% with no deviation from
HWE (p=0.98).
Statistical Analysis—Logistic and linear regression modelling was performed with
PLINK and SNPTEST28,29 assuming an additive genetic model. All the results presented
were unadjusted for population stratification as a genomic inflation factor of 1.003 and
0.998 was observed for logistic and linear regression analyzes respectively.
Data from the discovery cohort were also imputed to the HapMap II CEU panel of 2.2
million SNPs with program IMPUTE and tested for association with SNPTest taking into
account the imputed genotype probabilities30.
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As the two SNPs rs11212617 and rs609261 that were genotyped in the Go-DARTS sample
and the UKPDS sample respectively were in near complete LD (r2=0.997), we directly
combined the single marker association test results from the discovery cohort and the two
replication cohorts with the inverse variance fixed effect method as implemented in the R
package of GenABEL31.
Functional studies
KU-55933 is a cell-permeable ATP-competitive inhibitor of ATM (IC50 = 13 nM; Ki = 2.2
nM) with selectivity over other PIKK family kinases (IC50 = 2.5, 9.3, 16.6 μM for DNA-
PK, mTOR, PI 3-K, respectively; IC50 > 100 μM for PI 4-K and ATR)32. It is reported to
have little activity towards a panel of 70 conventional serine/threonine kinases. It has been
shown to inhibit ATM-dependent cellular protein phosphorylation following ionizing
radiation (IR) and sensitizes cells that express wild-type ATM (but not mutant ATM) to the
cytotoxic effects of IR and DNA-damaging agents33,34.
H4IIE cells were cultured in Dulbecco’s modified Eagle’s medium containing 5% (v/v) fetal
bovine serum to 80% confluence. For AMPK assays, cells were pretreated with 10 μM
KU55933 (30 min) prior to treatment with various concentrations of metformin for 1 hr.
Lysates were prepared (rapid lysis method35), centrifuged (4°C, 10 min 21,000 x g), and the
supernatants frozen for later analysis. AMPK activity was assayed in immunoprecipitates as
described35 using the AMARA peptide36.
To establish that the change in AMPK activity was due to regulation of phosphorylation of
AMPK and that this translated into changes in substrate phosphorylation, we used Western
Blotting to compare the phosphorylation status of Thr-172 of AMPK and Ser-79 of ACC (a
well characterized marker of AMPK activation). In both cases metformin induced
phosphorylation was partially reduced (Figure 3).
For these experiments, H4IIE cells were cultured to 80% confluence as above, then serum
starved for 16 hr, pretreated with KU55933 or vehicle (DMSO) for 1 hr then treated for 3 hr
with or without metformin. They were harvested as above. Proteins were resolved by SDS-
PAGE and transferred to nitrocellulose. The membrane was blocked in TBST containing 5%
milk for 1 hour, then incubated overnight at 4°C with anti-phospho-Thr172-AMPK antibody
(Cell Signaling, Beverly, MA), anti-phospho-Ser79 ACC antibody (Cell Signaling) or anti-
β-actin antibody (Sigma, Dorset, UK). Membranes were washed in TBST, incubated with
goat anti-rabbit IgG conjugated to horseradish peroxidase (Pierce, Chester, UK) then washed
again in TBST. The membrane was then developed using an ECL Western Blotting
Detection Kit (Amersham Biosciences) before exposure to X-Ray film (Thermo Scientific,
Waltham, MA).
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Figure 1.
Regional association plots around the ATM locus for the logistic regression analysis. The
solid and open triangles are from directly typed and imputed SNPs respectively
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Figure 2.
Effect of KU-55933 on AMPK activation by metformin
H4IIE cells were pre-treated with or without 10 μM KU-55933 for 30 min and then with
various concentrations of metformin for 1 hr, and AMPK activity measured; Results are
mean ± S.D. (n = 2); **significantly different from incubation without KU-55933 by 2-way
ANOVA (p<0.01).
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Figure 3.
A Western Blot comparing the phosphorylation status of Thr-172 of AMPK and Ser-79 of
ACC (a well characterized marker of AMPK activation). H4IIE cells were pre-treated with
or without 10 μM KU-55933 (KU) for 1 hour and then for 3 hours with or without 2.5mmol/
L metformin. Metformin induced phosphorylation of AMPK and subsequent
phosphorylation of ACC was partially reduced by KU-55933.
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